Quality of life and neurocognitive function in patients with active brain metastases of HER2-positive breast cancer treated with trastuzumab-deruxtecan

Patients with HER2+ breast cancer and active brain metastases maintained quality of life and neurocognitive function during trastuzumab deruxtecan therapy, according to results from the secondary endpoint analysis of the phase 2 TUXEDO-1 trial, presented during the 2022 ESMO Congress.